Published in Drug Week, December 16th, 2005
This is the first data to demonstrate that WelChol, a bile acid sequestrant, when added to statin therapy, reduces hs-CRP levels, which is a marker for inflammation and also a strong predictor of coronary heart disease (CHD) events.The addition of placebo to statin therapy led to a median...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.